Wyeth Peer Comparison

NSE: WYETH | BSE: 500095

₹1,333.85

₹-30.50 (-2.24%)

As on 09-Dec-2014IST

Market cap

₹3,032 Cr

Revenue (TTM)

₹742 Cr

P/E Ratio

27.7

P/B Ratio

9.2

Div. Yield

10.9 %

Edit

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	3,032	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	742	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	109.38	414.00	288.22	-371.81	387.35
Net Margin (%)	14.24	11.23	14.79	-3.93	26.01
RoE (%)	36.42	8.38	29.77	-3.85	25.18
Price to Earnings	27.72	78.49	103.71	--	69.57
Price-To-Book	9.15	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	679.33	4,830.36	41.58	--	76.11
Total Income	714.07	4,914.64	41.73	--	76.68
Total Expenditure	577.01	3,850.53	30.00	--	69.99
EBITDA	102.32	979.83	11.59	--	6.12
Depreciation	2.74	139.92	3.35	--	0.80
EBIT	99.58	839.91	8.24	--	5.32
Interest	0.44	83.35	2.34	--	1.58
Other Income	34.74	84.28	0.14	--	0.56
Exceptional Items	--	49.83	--	--	--
Profit before Tax	133.88	890.67	6.04	--	4.31
Provision for Tax	45.96	47.88	1.54	--	1.44
Profit after Tax	87.92	842.79	4.50	--	2.86

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	269.29	3,581.47	44.83	--	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	6.78	1,161.18	10.36	--	1.29
Current Liabilities	208.12	1,743.20	21.34	--	26.33
Total Liabilities	503.72	6,622.02	76.53	--	38.71

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	87.79	3,266.10	51.75	--	7.38
Current Assets	396.40	3,355.92	24.78	--	31.01
Total Assets	503.72	6,622.02	76.53	--	38.71
Total Debt*	2.50	1,906.08	21.09	--	12.17
Net Current Assets	188.28	1,612.72	3.44	--	4.68
Contingent Liabilities	126.37	267.40	4.70	--	--

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	118.83	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	28.69	-851.62	-5.46	--	-2.00
Cash from Financing Activities	-429.59	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	-282.08	23.35	0.25	--	-0.04

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	31.94	18.98	13.38	--	29.97
ROE (%)	21.03	30.04	19.08	--	30.26
ROA (%)	13.92	13.36	6.16	--	8.85
EBIT Margin (%)	20.18	22.03	28.21	--	8.78
Net Margin (%)	12.31	17.15	10.78	--	3.74
Cash Profit Margin (%)	12.93	20.32	18.86	--	4.81

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	0.15	-13.89	12.11	--	37.10
EBIT Growth (%)	-30.42	-49.66	21.82	--	30.95
Net Profit Growth (%)	-32.40	-46.64	58.36	--	39.55
EPS Growth (%)	-32.40	-56.04	58.36	--	39.55
Book Value Growth (%)	-52.49	36.37	21.09	--	32.03

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	23.01	6.59	0.00	--	0.00
Price / Book Value	7.51	1.55	0.00	--	0.00
Dividend Yield (%)	16.29	2.19	--	--	--
EV/EBITDA	13.63	5.73	3.52	--	2.02
Market Cap (₹ Cr)	2,022.77	5,016.58	0.00	--	0.00

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.01	0.54	0.47	--	1.13
Short term debt to equity ratio	--	0.06	0.23	--	0.84
Current Ratio	1.90	1.93	1.16	--	1.18
Quick Ratio	1.14	1.36	1.11	--	0.75
Interest Coverage	305.90	11.69	3.58	--	3.73

	Wyeth	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	7.36	9.96	33.85	--	17.81
Asset Turnover	1.11	0.77	0.57	--	2.35
Receivable days	24.61	54.33	106.93	--	58.46
Inventory Days	89.51	77.43	10.49	--	41.85
Payable days	158.44	120.43	213.33	--	91.25
Cash Conversion Cycle	-44.33	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.